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(54) NATIVE CHINESE HAMSTER OVARY CELL SECRETION SIGNAL PEPTIDES FOR 
PRODUCTION OF RECOMBINANT POLYPEPTIDES
(57) The invention provides a genetically modified
Chinese Hamster Ovary (CHO) cell for production of a
recombinant polypeptide, comprising a transgene en-
coding a CHO-derived signal peptide fused to a recom-
binant polypeptide, wherein said signal peptide is capa-
ble of directing co-translational transport of said polypep-
tide in the cell resulting in enhanced levels of polypeptide
secretion. The invention further provides a method for
producing a recombinant polypeptide by using the ge-
netically modified CHO cell. The invention further pro-
vides for the use of a CHO-derived signal peptide and a
transgene encoding said signal peptide to enhance pro-
duction of extracellular recombinant polypeptide by a ge-
netically modified CHO cell.
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Description
Field of the invention
[0001] The invention provides a genetically modified Chinese Hamster Ovary (CHO) cell for production of a recombinant
polypeptide, comprising a transgene encoding a CHO-derived signal peptide fused to a recombinant polypeptide, wherein
said signal peptide is capable of directing co-translational transport of said polypeptide in the cell resulting in enhanced
levels of polypeptide secretion. The invention further provides a method for producing a recombinant polypeptide by
using the genetically modified CHO cell. The invention further provides for the use of a CHO-derived signal peptide and
a recombinant gene encoding said signal peptide to enhance production of extracellular recombinant polypeptide by a
genetically modified CHO cell.
Background of the invention
[0002] Chinese hamster ovary (CHO) cells are currently the expression system of choice for production of therapeutic
proteins, mainly because they are able to produce proteins that require complex folding, post-translational modifications
such as glycoforms that are compatible with and bioactive in humans [Walsh G, 2014].
[0003] Accordingly, there exists an increasing interest in construction and development of mammalian cell factories
for production of therapeutic proteins. This interest has been further stimulated by the recent publication of the first
genome drafts of CHO cell lines [Xu X et al., 2011].
[0004] Construction of a system for secretory expression of recombinant proteins in CHO cells having high levels of
production requires a balance between gene expression, the protein transport process, cell viability and the composition
of the medium. For the process of protein transport specifically, the translocation of secretory proteins into the lumen of
the endoplasmic reticulum (ER) may be one of the limiting steps within the classical secretory pathway. In addition to
the components of the secretion apparatus, the signal peptides that channel the export proteins into the secretion
machinery play a key role in the translocation across the membrane.
[0005] Secreted proteins comprise an N-terminal signal peptide of 15-30 amino acids that is cleaved off while the
protein is translocated through the membrane of the ER [von Heijne G, 1985]. The structure of signal peptides from
various proteins is described to share common features consisting of three domains: an amino terminal positively charged
n-region, followed by a central hydrophobic h-region, and a neutral but polar c-region [von Heijne G, 1984, 1985]. Usually,
the cleavage sites have small and natural residues at position -3 and -1 from the cleavage site in order for cleavage to
occur. Beyond these overall patterns, no precise sequence conservation has been found or higher order structures [von
Heijne G, 1984].
[0006] Signal peptides are heterogeneous and may, to some degree, be functionally interchangeable between different
species [von Heijne G, 1985]. Although heterologous signal peptides from human protein interleukin-2 and interferon-
gamma growth factor-β 1 and 2, interferon (IFN-γ), human albumin, and immunoglobulin G have been used for expression
of therapeutic proteins in CHO cells, the limited yield of these proteins has been attributed to insufficient secretion
efficiency. Accordingly, there exists a need for signal peptides that can enhance the secretion efficiency and yield of
recombinant proteins expressed in CHO cells.
Summary of the invention
[0007] According to a first embodiment, the invention provides a recombinant gene for expression of a precursor
polypeptide, the gene comprising an in-frame fusion of:
a) a first nucleic acid molecule encoding a signal peptide, and
b) a second nucleic acid molecule encoding a recombinant polypeptide,
wherein the fused first and second nucleic acid molecule encode the precursor polypeptide, and wherein the signal
peptide is between 15 and 25 amino acid residues in length and comprises an amino acid sequence selected from the
group consisting of: SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6], SP4 [SEQ ID Neo.:8], SP5 [SEQ
ID No.:10], SP7 [SEQ ID No.:14] and SP11 [SEQ ID No.:22].
[0008] The recombinant polypeptide encoded by the second nucleic acid molecule in the recombinant gene may be
selected from the group consisting of a hormone, enzyme, immunoglobulin heavy chain, immunoglobulin light chain,
whole immunoglobulin, fragment antigen-binding (Fab) fragment, Fc fragment, single-chain variable fragment (scFv),
cytokine, interleukin, complement factor, coagulation factor, an extracellular matrix protein, and a soluble receptor.
[0009] According to a second embodiment, the invention provides a vector comprising the recombinant gene for
expression of a precursor polypeptide in a CHO cell.
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[0010] According to a third embodiment, the invention provides a genetically modified CHO cell transformed with a
recombinant gene for expression of a precursor polypeptide according to the invention.
[0011] The genetically modified CHO cell transformed with the recombinant gene according to the invention may be
derived from a CHO cell line selected from the group consisting of: CHO-K1, CHO-S or GS-CHO, CHO-Lec1, CHO-
Lec10, CHO-Lec13, CHO Pro-5, CHO DX B11 and CHO DG44 cells.
[0012] According to a fourth embodiment, the invention provides a method for producing a recombinant protein in vivo
comprising:
a) providing one or more genetically modified CHO cells transformed with a recombinant gene according to the
invention;
b) introducing said one or more genetically modified CHO cells into a culture medium to produce a culture;
c) incubating the culture;
d) recovering the produced recombinant polypeptide from the culture and optionally
e) purifying the recombinant polypeptide recovered.
[0013] According to fifth embodiment, the invention provides for the use of a signal peptide to enhance the production
of a recombinant polypeptide in a genetically modified CHO cell, wherein the signal peptide is fused to the recombinant
protein, and wherein the signal peptide is between 15 and 25 amino acid residues in length and comprises an amino
acid sequence selected from the group consisting of: SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6],
SP4 [SEQ ID No.:8], SP5 [SEQ ID No.: 10], SP7 [SEQ ID No.:14] and SP11 [SEQ ID No.:22].
[0014] The recombinant polypeptide fused to the signal peptide may be selected from the group consisting of a
hormone, enzyme, immunoglobulin heavy chain, immunoglobulin light chain, whole immunoglobulin, fragment antigen-
binding (Fab) fragment, Fc fragment, single-chain variable fragment (scFv), cytokine, interleukin, complement factor,
coagulation factor, an extracellular matrix protein, and a soluble receptor.
Description of the invention
Description of the figures:
[0015]
Figure 1. a) Venn diagrams of predicted proteins with signal peptide cleavage site by the three computational tools:
SignaIP, Phobius and PrediSi. The diagram represents the number of predicted signal peptides constituting the
secretome. b) Signal peptide library length distribution represented in quantities and as percentage of the total
amount of signal peptides. The 999 signal peptides represent the signal peptide library refined by predicted length
of the signal peptides were consistently within the secretome.
Figure 2 Hydropathy plots of the selected 13 native CHO cell signal peptide denoted SP1-SP13.
Figure 3 Cartoon showing the gene structure of expression vectors for expression of Rituximab antibody therapeutic
model glycoprotein.
Figure 4 Bar graph showing the integral of viable cells and cell-specific productivity, and titer of Rituximab by CHO
cells comprising vectors having a gene encoding a heterologous fusion of a CHO-derived signal peptide to the heavy
and light chains of Rituximab. Control vector constructs expressed in CHO cells, used as comparators, comprised
a gene encoding a heterologous fusion of a control signal peptide to the heavy and light chains of Rituximab. Vectors
encoding Rituximab with the different signal peptides were transfected into CHO-S cells in 96-half-deepwell micro-
plates. Rituximab titer was determined in supernatants obtained three days after transfection. a) Cell specific pro-
ductivity (qRituximab) normalized to SP_IFNγ, b) IgG titer normalized to SP_IFNγ and c) IVCD normalized to SP_IFNγ
are shown. Eight (14 for SP_IgG) separate transfections were performed in each experiment and experiments were
performed twice (n=2; 8 wells [n=2; 28 wells for SP_IgG]). Median and interquartile range are depicted. Statistically
significant differences (p<0.01) compared to SP_IFNγ are indicated in panels a and b (* = p<0.01; ** = p<0.001; n.s.
= not significant).
Abbreviations and terms:
[0016] gi number: (genInfo identifier) is a unique integer which identifies a particular sequence, independent of the
database source, which is assigned by NCBI to all sequences processed into Entrez, including nucleotide sequences
from DDBJ/EMBL/GenBank, protein sequences from SWISS-PROT, PIR and many others.
[0017] Amino acid sequence identity: The term "sequence identity" as used herein, indicates a quantitative measure
of the degree of homology between two amino acid sequences of substantially equal length. The two sequences to be
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compared must be globally aligned to give a best possible fit, by means of the insertion of gaps, where the aligned
sequences can end in gaps. The sequence identity can be calculated as ((Nref-Ndif)100)/(Nref), wherein Ndif is the total
number of non-identical residues in the two sequences when aligned and wherein Nref is the number of residues in one
of the sequences. Sequence identity can be calculated using the BLAST program e.g. the BLASTP program (Pearson
W.R and D.J. Lipman (1988)) (www.ncbi.nlm.nih.gov/cgi-bin/BLAST). Alignment of multiple sequences may be performed
with the global sequence alignment method ClustalW with default parameters as described by Thompson J., et al 1994,
available at http://www2.ebi.ac.uk/clustalw/.
[0018] Preferably, the numbers of substitutions, insertions, additions or deletions of one or more amino acid residues
in the polypeptide as compared to its comparator polypeptide is limited, i.e. no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
substitutions, no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 insertions, no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additions,
and no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 deletions. Preferably the substitutions are conservative amino acid
substitutions: limited to exchanges within members of group 1: Glycine, Alanine, Valine, Leucine, Isoleucine; group 2:
Serine, Cysteine, Selenocysteine, Threonine, Methionine; group 3: Proline; group 4: Phenylalanine, Tyrosine, Tryp-
tophan; Group 5: Aspartate, Glutamate, Asparagine, Glutamine.
[0019] Cell specific productivity of the recombinant polypeptide: the amount of recombinant polypeptide produced,
normalised to the number of cells and per day of cultivation.
[0020] Cognate native signal peptide is defined as a signal peptide that is found in nature, as a translational fusion,
at the amino-terminus of a polypeptide. A polypeptide can be expressed recombinantly in vivo, as a translational fusion
of the polypeptide with its cognate native signal peptide.
[0021] In frame translational fusion: the in-frame joining of two or more nucleic acid molecules, that each originally
coded for separate peptides and/or protein proteins, is used to artificially create a recombinant gene DNA, and such
that the reading frame of the joined nucleic acid molecules is preserved, and the translation product of the recombinant
gene is a fusion polypeptide
[0022] Native gene: endogenous gene in a microbial cell genome, homologous to host micro-organism.
[0023] Non-CHO-derived signal peptide: is a signal peptide that is not native to a CHO cell, and is not encoded as
an N-terminal signal peptide sequence by the native CHO genome.
[0024] Operably linked: a gene (nucleic acid molecule comprising a coding sequence) is operably linked to a promoter
when its transcription is under the control of the promoter and where transcription results in a transcript whose subsequent
translation yields the product encoded by the gene.
[0025] Recombinant gene: Recombinant gene is composed of nucleic acid molecules formed by laboratory methods
of genetic recombination (such as molecular cloning) to bring together genetic material from 2 or more sources, creating
sequences that would not otherwise be found in the genome.
[0026] Transgene: in the context of the invention is a gene or genetic material that has been transferred by any of a
number of genetic engineering techniques from one organism to another.
[0027] Titer of the recombinant polypeptide: concentration of the recombinant polypeptide in the culture medium.
[0028] Vector: The term "vector" refers to viral or non-viral, prokaryotic or eukaryotic, deoxyribonucleic acid, ribonucleic
acid or a nucleic acid analog, that is capable of carrying another nucleic acid. A vector may either carry a nucleic acid
into a cell, referred to as "host cell," so that all or a part of the nucleic acid is transcribed or expressed. Vectors are
frequently assembled as composites of elements derived from different viral, bacterial, or mammalian genes. Vectors
contain various coding and non-coding sequences including sequences coding for selectable markers (e.g., an antibiotic
resistance gene), sequences that facilitate their propagation in bacteria, or one or more transcription units that are
expressed only in certain cell types. For example, mammalian expression vectors often contain both prokaryotic se-
quences that facilitate the propagation of the vector in bacteria and one or more eukaryotic transcription units that are
expressed only in eukaryotic cells. It will be appreciated by those skilled in the art that the design of the expression
vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein
desired, etc.
Detailed description of the invention
[0029] The present invention is based on the first genome-wide analysis of the secretome to identify native secretion
signal peptides of CHO cells. The invention is further based on evidence that native CHO cell secretion signal peptides
can outperform the standard signal peptides currently used in biopharmaceutical production by enhancing the secretion
efficiency and yield of recombinant proteins expressed in CHO cells. In order to investigate native CHO cell secretion
signal peptides, in silico tools for prediction of the CHO-K1 secretome (Genbank assembly GCF_000223135.1) were
used to identify potential secretion signal sequences. The identification was based on the premise that signal peptides
must consistently rank as a potential secretion signal across a range of prediction tools, in order to efficiently narrow
down the search space and increase the possibility of detecting an efficient signal peptide. To analyze the functionality
and demonstrate secretion efficiency of native CHO cell secretion signal peptides, 13 predicted signal peptides were
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tested in vivo for polypeptide production and secretion as compared to signal peptides derived from human interferon-
gamma and interleukin-2, that are widely used in biopharmaceutical production, and two synthetic signal peptides.
I In silico identification of the CHO-K1 secretome
[0030] A combination of three signal peptide prediction tools facilitated a comprehensive bioinformatical analysis of
the CHO-K1 proteome, which resulted in generating a secretome of CHO cells, constituting 1,582 proteins; and generating
a signal peptide library constituting of 999 proteins (see Example 1). By additional use of predictors for transmembrane
helices (TMHs), subcellular localisation and protein function combined with references to the primary and secondary
literature, signal peptides of 13 proteins having potentially high secretory efficacy were selected (see Example 2).
II CHO-derived signal peptides for enhanced secretion of a recombinant polypeptide expressed in CHO cells
[0031] The present invention provides for the use of a CHO-derived signal peptide for enhancing the secretion of a
recombinant polypeptide in vivo in CHO cells, where the recombinant polypeptide is expressed as a precursor polypeptide
comprising the signal peptide N-terminally fused to the recombinant polypeptide. The signal peptide is selected from
the group consisting of signal peptides SP1, SP2, SP3, SP4, SP5, SP7 and SP11. Each of these signal peptides
preferably has a length of between 15 and 25 amino acid residues. The amino acid sequence of each signal peptide
(see Table 2) comprises (or consists of) the following sequence: SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ
ID No.:6], SP4 [SEQ ID No.:8], SP5 [SEQ ID No..:10], SP7 [SEQ ID No.:14] and SP11 [SEQ ID No.:22].
[0032] From amongst the 13 selected signal peptides, the CHO-derived signal peptides SP1, SP2, SP3, SP4, SP5,
SP7 and SP11 (see Table 2) were all demonstrated to enhance the secretion of a recombinantly expressed polypeptide
in vivo in CHO cells as compared to control. This was demonstrated for the biopharmaceutical model antibody glycoprotein
(Rituximab) and for secreted alkaline phosphatase (SEAP). These 7 high-performing CHO-derived signal peptides also
improved the cell-specific productivity and titer of Rituximab when compared to the widely used signal peptides derived
from human interferon-gamma, IFNγ (SP_IFNγ). Additionally the cell-specific productivity and titer of Rituximab when
using any of the 7 high-performing CHO-derived signal peptides was also enhanced when compared to two computer-
generated synthetic signal peptide sequences that have shown promising secretion efficiency of SEAP in HEK293 cells
[Barash S et al., 2002].
[0033] The recombinant polypeptide, whose expression and secretion in a CHO cell is enhanced by use of a CHO-
derived signal peptide, may be any polypeptide that is secreted by a CHO cell. The recombinant polypeptide may be
chosen from a hormone, an enzyme, an immunoglobulin heavy chain or light chain, a whole immunoglobulin or any
fragment derived from an immunoglobulin, a protein involved in the immune response such as cytokines, interleukins,
complement factors, a chimeric protein, or another therapeutic protein such as a coagulation factor, an extracellular
matrix protein, or a soluble receptor. Preferably the recombinant polypeptide is an immunoglobulin heavy chain and/or
a light chain, a whole antibody or a fragment thereof (e.g. fragment antigen-binding (Fab) fragment, Fc fragment, single-
chain variable fragment (scFv)).
III A recombinant gene for enhanced expression of a polypeptide in vivo in CHO cells
[0034] The invention further provides a first nucleic acid molecule encoding a CHO-derived signal peptide for enhancing
the secretion of a recombinantly-expressed polypeptide in vivo in CHO cells, where the signal peptide is selected from
the group consisting of signal peptides SP1, SP2, SP3, SP4, SP5, SP7 and SP11. Each of these signal peptides
preferably has a length of between 15 and 25 amino acid residues (see Table 2). The amino acid sequence of each
signal peptide (see Table 2) encoded by the nucleic acid molecule comprises (or consists of) the following sequence:
SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6], SP4 [SEQ ID No.:8], SP5 [SEQ ID No.:10], SP7 [SEQ
ID No.:14] and SP11 [SEQ ID No.:22].
[0035] When using the nucleic acid molecule, encoding the CHO-derived signal peptide, for the purpose of enhancing
the secretion of a recombinantly expressed polypeptide in vivo in CHO cells, the signal peptide coding sequence of the
nucleic acid molecule is fused in frame to a nucleic acid molecule encoding the recombinant polypeptide to be expressed
in a CHO cell. A recombinant gene comprises the in-frame fusion of the nucleic acid molecule encoding the signal peptide
and the nucleic acid molecule encoding the recombinant polypeptide. For the purpose of enhancing the secretion of a
recombinantly expressed polypeptide in vivo in CHO cells, the recombinant gene may be operably linked to a nucleic
acid molecule comprising a promoter and additionally may be operably linked to a nucleic acid molecule functioning as
a terminator. The recombinant gene, comprising nucleic acid sequences functioning as a promoter and/or terminator,
may then be introduced into a CHO cell, where subsequent incubation of the cell under suitable cultivation conditions
facilitates expression and secretion of the recombinant polypeptide.
[0036] The recombinant gene of the invention encodes a fusion polypeptide, comprising a CHO-derived signal peptide
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(as defined above) fused to a polypeptide, where the polypeptide is preferably heterologous with respect to the signal
peptide; and where the amino acid sequence of the encoded fusion is not therefore to be found in nature. For expression
of the fusion polypeptide, the recombinant gene is transferred into a host CHO cell where it may be expressed as a
transient or a stably integrated transgene. The fusion polypeptide encoded by the transgene is a precursor polypeptide,
where the signal peptide at its amino-terminal end causes the precursor polypeptide to pass into the rough endoplasmic
reticulum (RER) where it will be matured, and where the signal peptide is normally cleaved off by a peptidase at the
signal peptide cleavage site.
[0037] The recombinant polypeptide encoded by the recombinant gene may be chosen from a hormone, an enzyme,
an immunoglobulin heavy chain or light chain, a whole immunoglobulin or any fragment derived from an immunoglobulin,
a protein involved in the immune response such as cytokines, interleukins, complement factors, a chimeric protein, or
another therapeutic protein such as a coagulation factor, an extracellular matrix protein, or a soluble receptor. Preferably
the recombinant polypeptide is an immunoglobulin heavy chain and/or a light chain, a whole antibody or a fragment
thereof (e.g. fragment antigen-binding (Fab) fragment, Fc fragment, single-chain variable fragment (scFv)).
[0038] According to one embodiment the recombinant polypeptide is an immunoglobulin composed of a heavy chain
and/or a light chain or comprises a heavy chain and/or a light chain variable domain, where the immunoglobulin heavy
and light chain (or heavy chain and/or a light chain variable domain) is selected from the group of: rituximab (having
heavy chain [SEQ ID No.:28] and the light chain [SEQ ID No.:30]; Abciximab; Adalimumab (heavy chain [SEQ ID No.:
98] and light chain [SEQ ID No.: 99] variable domains); Alemtuzumab (complete light chain [SEQ ID No.: 100] and
complete heavy chain [SEQ ID No.:101]; Altumomab pentetate; Arcitumomab; Atlizumab (= tocilizumab); Basiliximab
(heavy chain [SEQ ID No.: 102] and light chain [SEQ ID No.: 103] variable domains); Bectumomab; Belimumab (heavy
chain [SEQ ID No.:104] and light chain [SEQ ID No.:105] variable domains); Besilesomab; Bevacizumab (complete
heavy chain [SEQ ID No.:106] and complete light chain [SEQ ID No.: 107]; Biciromab; Canakinumab (heavy chain [SEQ
ID No.:108] and light chain [SEQ ID No.: 109] variable domains); Capromab pendetide; Catumaxomab; Certolizumab
pegol; Cetuximab (light chain [SEQ ID No.:110] and heavy chain [SEQ ID No.:111] variable domains); Clivatuzumab
(complete light chain [SEQ ID No.: 112] and complete heavy chain [SEQ ID No.:113]); Daclizumab (complete light chain
[SEQ ID No.:114] and complete heavy chain [SEQ ID No.:115]); Denosumab (heavy chain [SEQ ID No.:116] and light
chain [SEQ ID No.:117] variable domains)]; Eculizumab (complete heavy chain [SEQ ID No.:118] and complete light
chain [SEQ ID No.:119]); Edrecolomab [SEQ ID No.:]; Efalizumab (light chain [SEQ ID No.:120] and heavy chain [SEQ
ID No.: 121] variable domains); Efungumab; Ertumaxomab; Etaracizumab (complete heavy chain [SEQ ID No.: 122]
and complete light chain [SEQ ID No.: 123]); Fanolesomab; Fontolizumab (complete light chain [SEQ ID No.: 124] and
complete heavy chain [SEQ ID No.: 125]); Gemtuzumab ozogamicin; Girentuximab (complete light chain [SEQ ID No.:
126] and complete heavy chain [SEQ ID No.:127]); Golimumab (heavy chain [SEQ ID No.:128] and light chain [SEQ ID
No.: 129] variable domains)]; Ibritumomab tiuxetan (heavy chain [SEQ ID No.:130] and light chain [SEQ ID No.:131]
variable domains); Igovomab; Imciromab; Infliximab (heavy chain [SEQ ID No.: 132] and light chain [SEQ ID No.:133]
variable domains); Ipilimumab (heavy chain [SEQ ID No.:134] and light chain [SEQ ID No.: 135] variable domains);
Labetuzumab (complete heavy chain [SEQ ID No.:136] and complete light chain [SEQ ID No.:137]); Mepolizumab (heavy
chain [SEQ ID No.: 138] and light chain [SEQ ID No.: 139] variable domains); Motavizumab (complete light chain [SEQ
ID No.: 140] and complete heavy chain [SEQ ID No.:141]); Muromonab-CD3; Natalizumab (light chain [SEQ ID No.:
142] and heavy chain [SEQ ID No.: 143] variable domains); Nimotuzumab (light chain [SEQ ID No.: 144] and heavy
chain [SEQ ID No.: 145] variable domains)]; Nivolumab (complete heavy chain [SEQ ID No.: 146] and complete light
chain [SEQ ID No.: 147]); Nofetumomab merpentan; Obinutuzumab (complete heavy chain [SEQ ID No.: 148] and
complete light chain [SEQ ID No.: 149]); Ofatumumab (heavy chain [SEQ ID No.: 149] and light chain [SEQ ID No.: 150]
variable domains); Omalizumab (complete heavy chain [SEQ ID No.: 152] and complete light chain [SEQ ID No.: 153]);
Oregovomab; Palivizumab (complete heavy chain [SEQ ID No.: 154] and complete light chain [SEQ ID No.: 155]);
Panitumumab (complete heavy chain [SEQ ID No.: 156] and complete light chain [SEQ ID No.: 157]); Pemtumomab;
Pertuzumab (heavy chain [SEQ ID No.: 158] and light chain [SEQ ID No.: 159] variable domains); Ramucirumab (complete
heavy chain [SEQ ID No.:160] and complete light chain [SEQ ID No.:161]); Ranibizumab (heavy chain [SEQ ID No.:162]
and light chain [SEQ ID No.:163] variable domains); Rovelizumab; Ruplizumab (heavy chain [SEQ ID No.: 164] and light
chain [SEQ ID No.:165] variable domains); Sulesomab; Tacatuzumab tetraxetan; Tefibazumab; Tositumomab; Trastu-
zumab (complete heavy chain [SEQ ID No.:166] and complete light chain [SEQ ID No.:167]); Trastuzumab emtansine
(complete heavy chain [SEQ ID No.:168] and complete light chain [SEQ ID No.:169]); Ustekinumab (complete light chain
[SEQ ID No.: 170] and complete heavy chain [SEQ ID No.:171]); Visilizumab (complete light chain [SEQ ID No.:172]
and complete heavy chain [SEQ ID No.: 173]) Votumumab; Zalutumumab (light chain [SEQ ID No.: 174] and heavy
chain [SEQ ID No.: 175] variable domains); and Zanolimumab (light chain [SEQ ID No.:176] and heavy chain [SEQ ID
No.:177] variable domains).
[0039] A DNA molecule capable of functioning as a promoter in a CHO cell that may be operably linked to the recom-
binant gene, may be selected from among a number of constitutive or inducible promoters known in the art. As an
example, a suitable promoter for directing constitutive or inducible expression of the recombinant gene in a CHO cell
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may be selected from the cytomegalovirus (CMV) promoter [SEQ ID No.: 31]; SV40 early promoter (SV40pA) GenBank:
E00567.1 [SEQ ID No.: 32].
[0040] A DNA molecule capable of functioning as a terminator of a recombinant gene for expression of a polypeptide
in a CHO cell, that may be operably linked to the recombinant gene, may be selected from the bovine growth hormone
polyadenylation (bgh-PolyA) signal [SEQ ID No.:32] (nucleotides 1943-2167 in GenBank E00847.1); SV40 poly ade-
nylation signal [SEQ ID No.:34] (nucleotides 5929-6181 in GenBank: A70359.1)
IV: A genetically modified CHO cell capable of enhanced secretion of a recombinant polypeptide
[0041] The invention further provides a genetically modified CHO cell comprising a transgene. The transgene, intro-
duced into the CHO cell, is a recombinant gene comprising a coding sequence for a CHO-derived signal peptide for
enhancing the secretion of a recombinantly expressed polypeptide in vivo (as described in Section III). The signal peptide
is selected from the group consisting of signal peptides SP1, SP2, SP3, SP4, SP5, SP7 and SP11. Each of these signal
peptides preferably has a length of between 15 and 25 amino acid residues (see Table 2). The amino acid sequence of
each signal peptide (see Table 2) encoded by the nucleic acid molecule comprises (or consists of) the following sequence:
SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6], SP4 [SEQ ID No.:8], SP5 [SEQ ID No.:10], SP7 [SEQ
ID No.: 14] and SP11 [SEQ ID No.:22].
[0042] The coding sequence of the transgene encodes a fusion polypeptide, comprising a CHO-derived signal peptide
(as defined above) fused in-frame to a recombinant polypeptide. The transgene may be localized on a transiently
expressed vector in the genetically modified CHO cell or the transgene (transformed into the CHO cell) may be stably
integrated into the genome of the CHO cell. Suitable vectors for transient expression of a transgene in the genetically
modified CHO cell of the invention are well known in the art; for example pcDNA3.1 from Thermo Fischer, or CHEF1
vectors from CMC Biologics.
[0043] The CHO cell may be obtained from a number of biological resource centers such as the European Collection
of Cell Cultures (ECACC). A number of variants of the first isolated CHO-K1 cell line are available. A suitable CHO cell
line for expression of a secreted recombinant protein according to the invention includes CHO-K1, CHO-S or GS-CHO,
CHO-Lec1, CHO-Lec10, CHO-Lec13, CHO Pro-5, CHO DX B11 and CHO DG44 cells, in particular CHO-S or GS-CHO.
V: A method for producing a recombinant polypeptide in a genetically modified CHO using a signal peptide of 
the invention
[0044] According to a further embodiment, the invention provides a method for enhancing expression of a recombinant
protein in a CHO cell, comprising:
a. providing a CHO cell comprising a transgene, wherein said transgene comprises:
i. a first nucleic acid molecule encoding a CHO-derived signal peptide, and
ii. a second nucleic acid molecule encoding a recombinant polypeptide;
wherein said first nucleic acid molecule is translationally fused in-frame to said second nucleic acid molecule and
wherein the amino acid sequence of said CHO-derived signal peptide is selected from the group consisting of signal
peptides SP1, SP2, SP3, SP4, SP5, SP7 and SP11, and
b. culturing said CHO cell in a culture medium; and
c. recovering said recombinant protein from the culture.
[0045] The transgene, comprising the recombinant gene described in Section III, may be localized on a transiently
expressed vector in the genetically modified CHO cell. Alternatively, the transgene transformed into the CHO cell, may
be stably integrated into the genome of the CHO cell. The recombinant gene may be introduced into the host CHO cell
by transfection. For example, vector DNA comprising the recombinant gene can be complexed with lipid reagents to
mediate efficient delivery into the cell’s nucleus. For example, cationic lipid-based reagents spontaneously form con-
densed nucleic acid-cationic lipid reagent complexes via electrostatic interactions between the negatively charged nucleic
acid and the positively charged head group of the synthetic lipid reagent. These complexes are believed to be taken up
by the cell through endocytosis and then released in the cytoplasm. Once in the cell, transfected DNA is translocated
to the nucleus to be expressed.
[0046] Approximately one in 104 transfected cells will stably integrate the transgene DNA, although the efficiency
varies with cell type; where integration is most efficient when linear DNA is used. The selection of genetically modified
CHO cells that stably express transfected DNA can be achieved by including a selectable marker on the DNA vector
used for transfection, and then applying the corresponding selective pressure to the cells after a short recovery period.
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[0047] The genetically modified CHO cell comprising the transgene of the invention is cultured in a growth medium
and under conditions that support protein synthesis and production of the recombinant protein encoded by the transgene.
Suitable cultivation conditions for production of a recombinant protein by a genetically modified CHO cell are described
in Animal Cell Technology: From Biopharmaceuticals to Gene Therapy (2008) by editors Leda R. Castilho et al.
[0048] The polypeptide encoded by the transgene is a precursor polypeptide comprising the CHO-derived signal
peptide fused to the recombinant protein. The signal peptide of the precursor polypeptide is co-translationally cleaved
off the precursor polypeptide, such that the amino acid sequence of the recombinant protein secreted by the CHO cell
is that of the mature recombinant protein.
[0049] The method of the invention, using CHO cells transfected with a transgene of the invention (encoding a precursor
polypeptide comprising in-frame translational fusion of the CHO-derived signal peptide to the recombinant protein), is
characterized by an enhanced cell-specific productivity and/or titer of the recombinant polypeptide, as compared to a
transgene encoding the recombinant protein translationally fused to its native homologous signal peptide. Preferably,
the titer and cell-specific productivity of the recombinant polypeptide by the transfected CHO cells of the invention is
enhanced as compared to a transgene encoding the recombinant protein that is in-frame translationally fused to a signal
peptide derived from human interferon-gamma or interleukin-2, or a cognate native signal peptide of the recombinant
protein, or a non-CHO derived signal peptide.
VI Methods for producing a transgene of the invention
[0050] Integration and transient expression vectors suitable for cloning and introducing a transgene encoding a trans-
lational fusion of the CHO-derived signal peptide of the invention to a recombinant polypeptide are commercially available
and known to those skilled in the art (e.g. Animal Cell Technology: From Biopharmaceuticals to Gene Therapy (2008)
by editors Leda R. Castilho et al.). Suitable methods for transfection to integrate the transgene into a CHO cell are given
in Section V. Examples of recombinant expression of transgenes encoding a translational fusion of the CHO-derived
signal peptide of the invention to a recombinant polypeptide in a CHO cell of the invention is demonstrated in Example 3.
VI Evaluation of the Level of Recombinant Polypeptide Secreted
[0051] Methods for detecting and quantifying extracellular recombinant polypeptide produced by a CHO cell of the
invention, depends on the polypeptide expressed by the transgene. For example, when the recombinant polypeptide is
an IgG, suitable methods include the Fast ELYSA kit (RD-biotech) according to the supplier’s instructions. The optical
density is read with a spectrophotometer at 450 nm. The antibody concentration is determined in comparison with a
standard range contained in the kit.
Examples
Example 1 in silico prediction of the CHO-K1 secretome
1.1 In silico analysis:
[0052] The proteome (Genbank assembly GCF_000223135.1) of the CHO-K1 cell line (Baycib-Hizal et al., 2012) was
used for the in silico construction of a CHO cell signal peptide library. The three computational programs SignalP 4.1
[Petersen TN et al, 2011], Phobius [Käll L, et al., 2004], and PrediSi [Hiller K et al., 2004] were applied to predict signal
peptide cleavage sites in order to generate a CHO-K1 secretome and create signal peptide library. Phobius also comprises
a TMH predictor in order to discriminate between signal peptides and helices and thereby increase the signal peptide
prediction accuracy by [Käll L, et al., 2004].
[0053] Transmembrane predictions of the signal sequences were performed using the TMHMM server [Krogh A et al,
2001]. Subcellular localisation of the secretome was analysed with Yloc+ [Briesemeister S., et al, 2010] and SubCellProt
[Garg P. et al, 2009]. Finally, protein function was determined by comparing functional protein domains with gene
annotation predicted by HmmScan [Finn RD et al, 2011] and Genbank, respectively. The hydrophobicity of selected
signal peptides was estimated using the ExPASy program [Gasteiger E. et al., 2003] and the Kyte & Doolittle scale [Kyte
J, et al., 1982] using a sliding window of five residues. OligoAnalyser 3.1 [Owczarzy R, et al., 2008] was used for analysing
potential primer secondary structures. All the servers for the different bioinformatic tools used in this study are listed in
Table 1.
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1.2 Results
[0054] Of the 24,238 (GenBank: AFTD00000000.1) putative CHO-K1 protein sequences, a total of 8.502 proteins
were predicted to have a signal peptide. SignalP predicted 2,009 (8.3% of total number of protein sequences) proteins
to encode a signal peptide. In comparison Phobius and PredSi predicted 2,802 (11.6 %) and 3,691 (15.2 %) proteins
with signal peptide, respectively (see Figure 1 a). 1,582 (6.5 %) proteins were predicted by all three methods to encode
a signal peptide. Further, to increase the likelihood of precise prediction of the signal peptides, the predicted length of
the signal peptides were integrated. Thereby, out of the 1,582 predicted signal peptides, 999 (4.1% of total number of
protein sequences or 63 % of predicted secreted protein) were predicted to have the same length by all three methods.
2,352 proteins (28% of predicted secreted protein) were predicted by only one model.
[0055] These 999 predicted signal peptides constituted the signal peptide library of CHO-K1. The length of the signal
peptide library varies from 16 to 49 residues, with a mean length of 21.9 residues (see Figure 1b). 64.8% of the signal
peptides have a length between 18 and 24 residues, with 19 residues as the most common length, constituting 15.8 %
of the library. Only 53 (5.3 %) signal peptides were predicted to be longer than 30 residues.
Example 2 In silico selection of a small subset of diverse and potentially potent signal peptides
2.1 In silico selection methods
[0056] A small subset of diverse and potentially potent native CHO cell signal peptides signal peptides was first
screened for in silico for subsequent in vivo testing. The selection was performed in several steps using bioinformatics
prediction tool for analyzing secondary structures, functional domains, cellular location of proteins, and natural function.
Firstly, as proteins destined to be membrane proteins can also encode a SP that resembles those of secreted proteins,
potential membrane signal peptide were excluded from the library of 999 signal peptides. Exclusion was based on the
presence of transmembrane helices (TMHs) structures, indicative of membrane location [48]. Using the TMHMM server
[Krogh A et al., 2001] which is designed for predicting TMHs, a total of 337 proteins (33.7 %) were then discarded as
signal peptides. Secondly, the remaining 662 signal peptides were analysed for the presence of functional domains in
the protein by the HMMScan server [Finn RD et al., 2011] and compared to Genbank annotations, which further reduced
the number of potential signal peptides to 50. These 50 signal peptides were then subjected to: 1) Predicting the proteins
subcellular location using both Yloc+ [Briesemeister S, et al., 2010] and SubCellProt [Garg P et al., 2009] for evidence
of secretion and natural function; 2) hydrophobicity patterns were predicted by use of the CLC Main Workbench (CLC
bio, Denmark) with Kyte & Doolittle scale [Kyte J,et al., 1982] for determination of secretion efficiency; 3) potential hairpin
structures within the signal peptide were assessed by OligoAnalyzer 3.1.
2.2 Results:
[0057] A total of 13 signal peptides were selected by this procedure, the peptides having different lengths, hydropho-
bicity and a variety of origins e.g. hormone and enzyme selected (Table 2 and Figure 2).
Table 1. In silico tools used for prediction of secretome and signal peptide library construction.
Prediction tool Prediction URL Reference
SignalP 4.1 Signal peptide http://www.cbs.dtu.dk/services/Signal P/
Phobius Signal peptide http://phobius.binf.ku.dk
PrediSi Signal peptide http://www.predisi.de
TMHMM Transmembrane 
helix
http://www.cbs.dtu.dk/services/TMHM M
HMMScan Protein domain http://hmmer.janelia.org/search/hmms can
Genbank Protein annotation http://www.ncbi.nlm;nih.gov/genbank
SubCellProt Subcellular 
localisation
http://www.databases.niper.ac.in/SubC ellProt
Yloc Subcellular 
localisation
http://abi.inf.unituebinaen.de/Services/YLoc/
webloc.cgi
OligoAnalys er 3.1 Primer secondary 
structures
http://eu.idtdna.com/analyser/Applicat ions/
OligoAnalyser/
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Example 3 In vivo testing of native CHO signal peptides secretion rate of Rituximab
[0058] Expression vectors were constructed comprising a nucleotide coding sequence for each of the 13 selected
native CHO signal peptides fused to the coding sequence for the therapeutic model glycoprotein: Rituximab IgG antibody
(heavy chain [SEQ ID No. 27] and light chain [SEQ ID No. 29]), in substitution for the nucleotide sequences encoding
their respective native signal peptides. For comparison, expression plasmids comprising the coding sequences for two
synthetic signal peptides (SYN1 [SEQ ID No. 36] and SYN2 [SEQ ID No. 38) and the signal peptide from human interferon-
Table 2. Characteristics of the selected CHO signal peptides and comparator signal peptides
Name Accession 
number
Amino acid sequence Length 
[aa]
D 
scorea
Sub-cellular 
Localizati onb
Hydrop 
hobicity 
c[%]
SEQ 
ID 
No.:
SP1 EGW05316 16 0.804 E/EE 75 2
SP2 EGW11684 18 0.913 E/EE 83 4
SP3 EGW05785 21 0.769 E/EE 76 6
SP4 EGW08182 17 0.931 E/EE 88 8
SP5 EGW00421 22 0.881 E/EE 63 10
SP6 EGW08477 24 0.871 E/EE 83 12
SP7 EGW07653 21 0.736 P/EE 76 14
SP8 EGW05330 18 0.913 E/EE 83 16
SP9 EGW00575 16 0.890 E/EE 75 18
SP10 EGV97682 19 0.899 E/EE 74 20
SP11 EGW15258 17 0.890 LE/LL 76 22
SP12 EGV95205 23 0.868 E/EE 65 24
SP13 EGV92826 21 0.891 E/EE 71 26
Abbreviations: E=Extracellular space, L=Lysozome and P=Plasma membrane. SubCellProt uses two models for the
prediction hence the double abbreviation.
a D score calculated by SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/).
b Location predicted by Yloc+ / SubCellProt.
c Percentage of hydrophobic amino acids in each signal sequence, calculated with amino acids G, A, V, L, I, M, F,
W, and P defined as hydrophobic and any other amino acid defined as hydrophilic.
EP 3 323 826 A1
11
5
10
15
20
25
30
35
40
45
50
55
gamma, IFNγ (SP_IFNγ) [SEQ ID No. 40] were each similarly constructed for expression of the Rituximab IgG antibody
(Table 3). These reference signal peptides were chosen as comparators since they have been used (or are commonly
used) in both commercial protein production and gene therapy research. The rate of protein secretion facilitated by the
signal sequences was analyzed by use of a high-throughput screening platform of transient expression in CHO-S cells.
3.1 Vector design and construction
[0059] The genes encoding the different signal peptides, N-terminally fused to the Rituximab light and heavy chains,
were located on the same vector, the two genes being expressed under the control of the human elongation factor 1α
promoter (EF-1α) and cytomegalovirus (CMV) promoter, respectively (Figure 3). The vectors were constructed with
uracil-specific excision reagent (USER) cloning method according to previously described [Lund AM et al., 2014]. The
nucleotide components of the vector were amplified with uracil-containing primers (DNA Technologies, Leuven, Belgium)
and proofreading polymerase PfuX7 [Nørholm MH, 2010]. The CMV promoter, Neomycin resistance gene (NeoR) ex-
pression cassette (pSV40-NeoR-SV40 pA), and bovine growth hormone polyadenylation signal (BGHpA) coding se-
quence were each amplified directly from commercial expression vectors. The promoter of the Human elongation factor
gene (EF-1α) promoter, and the coding sequence for the model antibody Rituximab heavy (HC) and light (LC) chains
were synthesized. Primer sequences and all vectors used as PCR templates are listed in Table 4 and 5, respectively.
Following purification of PCR products by agarose gel separation and illustra GFX Gel Band Purification Kit (GE Health-
care), the purified PCR fragments were assembled with USER enzyme (New England Biolabs, Ipswich, MA) and trans-
formed into E. coli Mach1 competent cells (Life Technologies, Leuven, Belgium). Vectors were purified from transformants
selected on LB agar plates with ampicillin. All constructs were verified with sequencing and purified using NucleoBond
Xtra Midi EF (Macherey-Nagel, Düren, Germany) or Qiagen Plasmid Plus Midi kit (Qiagen, CA, USA) according to
manufacturer’s instructions.
Table 3. Signal peptides used for comparison with native CHO signal peptides
Name Amino acid sequence Length [aa] Reference SEQ ID No.
SYN1 MWWRLWWLLLLLLLLWPMVWA 21 [1] 36
SYN2 MRPTWAWWLFLVLLLALWAPARG 23 [1] 38
IFNγ MKYTSYILAFQLCIVLGSAG 20 [2] 40
[1]: Barash S et al., 2002
[2]: UniProtKB - P01579
Table 4. Primer sequences
Name Purpose Sequence (5’→  3’) SEQ ID 
No.
CMV_FW CMV ACGTCGCUCGATGTACGGGCCAGATATAC 41
CMV_RV CMV ATCGCACUATTTCGATAAGCCAGTAAGCAGT 42
BGH pA_FW BGHpA ACACAGTCUCTGTGCCTTCTAGTTGCCAGC 43
BGH pA_RV BGHpA ACGCAAGUCCATAGAGCCCACCGCATC 44
BGHpA_HC-Ritux_
FW
BGHpA (HC-
Rituximab)
ATTAAGACUCTGTGCCTTCTAGTTGCCAGC 45
BGHpA_HC-Ritux_
RV
BGHpA (HC-
Rituximab)
AGGCATAGUCCATAGAGCCCACCGCATC 46
EF1alpa_FW EF1alpa ACTATGCCUGTGAGGCTCCGGTGCCCG 47
EF1alpa_RV EF1alpa ACCAGCGCUTCACGACACCTGAAATGGAAGAA 48
NaSP-HC-Rituxi_FW Native SP_HC-
Rituximab
AGTGCGAUATGGGCTGGTCCTGCATCA 49
HC-Rituxi_RV Native SP_HC-
Rituximab
AGTCTTAAUTCACTTGCCGGGGCTCAG 50
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(continued)
Name Purpose Sequence (5’→  3’) SEQ ID 
No.
HC-Rituxi-FW SPX_HC-Rituximab AGCAGCCUGGCGCCGAG 51
SP1-HC-Ritux-RV CMV_SP1 52
SP2-HC-Ritux-RV CMV_SP2 53
SP3-HC-Ritux-RV CMV_SP3 54
SP4-HC-Ritux-RV CMV_SP4 55
SP5-HC-Ritux-RV CMV_SP5 56
SP6-HC-Ritux-RV CMV_SP6 57
SP7-HC-Ritux-RV CMV_SP7 58
SP8-HC-Ritux-RV CMV_SP8 59
SP9-HC-Ritux-RV CMV_SP9 60
SP10-HC-Ritux-RV CMV_SP10 61
SP11-HC-Ritux-RV CMV_SP11 62
SP12-HC-Ritux-RV CMV_SP12 63
SP13-HC-Ritux-RV CMV_SP13 64
SYN1-HC-Ritux-RV CMV_SYN1 65
SYN2-HC-Ritux-RV CMV_SYN2 66
SP-IFNy-HC-Ritux-
RV
CMV_SPIFNy 67
SP1-LC-Ritux_FW SP1_LC-Rituximab 68
SP2-LC-Ritux_FW SP2_LC-Rituximab 69
SP3-LC-Ritux_FW SP3_LC-Rituximab 70
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(continued)
Name Purpose Sequence (5’→  3’) SEQ ID 
No.
SP4-LC-Ritux_FW SP4_LC-Rituximab 71
SP5-LC-Ritux_FW SP5_LC-Rituximab 72
SP6-LC-Ritux_FW SP6_LC-Rituximab 73
SP7-LC-Ritux_FW SP7_LC-Rituximab 74
SP8-LC-Ritux_FW SP8_LC-Rituximab 75
SP9-LC-Ritux_FW SP9_LC-Rituximab 76
SP10-LC-Ritux_FW SP10_LC-Rituximab 77
SP11-LC-Ritux_FW SP11_LC-Rituximab 78
SP12-LC-Ritux_FW SP12_LC-Rituximab 79
SP13-LC-Ritux_FW SP13_LC-Rituximab 80
SYN1-LC-Ritux_FW SYN1_LC-Rituximab 81
SYN2-LC-Ritux_FW SYN2_LC-Rituximab 82
IFNy-LC-Ritux_FW SPIFNy_LC-Rituximab 83
NaSP-LC-Ritux FW Native SP_LC-
Rituximab
AGCGCTGGUATGGGCTGGTCCTGCATC 84
LC-Ritux RV SPX_LC-Rituximab AGACTGTGUTCAGCACTCGCCCCGGTTGAAA 85
Vector_Mam-RV Backbone AGCGACGUGAGTCGAATAAGGGCGACACC 86
Vector_Mam-FW Backbone ATTAAGCUAGTGAGTCGAATAAGGGCGACA 97
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3.2 Cell cultivation
[0060] CHO-S suspension cells obtained from Life Technologies were maintained in CD-CHO medium (Gibco, Life
Technologies) supplemented with 8 mM L-Glutamine (Gibco, Life Technologies) and 1:500 Anti-Clumping Agent (Gibco,
Life Technologies). CHO-S cells were expanded in Erlenmeyer cell culture flasks (Corning, Sigma-Aldrich) in a humidified
incubator at 37°C with 5 % CO2.
3.3 Transfection and cell counting: Signal peptide- Rituximab constructs
[0061] Experiments were performed in pre-sterilized polystyrene 96-square System Duetz half-deep well-microplates
(CR1496c, Enzyscreen, Haarlem, Netherlands) capped with autoclaved low-evaporation sandwich Duetz covers
(CR1296a, Enzyscreen). Plates were incubated in a humidified S41i incubator shaker (New Brunswick, Eppendorf,
Hamburg, Germany) at the following conditions: 37°C, 5% CO2, 325 rpm, 25 mm orbit. 250 mL 1x106 cells/mL CHO-S
cells were transfected using FreeStyleTM MAX reagent as previously described [Hansen HG et al., 2015]. The day after
transfection, anti-clumping agent was added to all wells reaching a final concentration of 2 mL/mL. VCD and viability
were measured every day on the Celigo Imaging Cell Cytometer using Hoechst-33342 and propidium iodide as previously
described [42]. Transfection efficiency was based on green fluorescence of cells transfected with pmaxGFP (Lonza
Group AG, Basel, Switzerland). Transfection efficiency was determined at previously described [Hansen HG et al., 2015].
Supernatant samples were obtained three days post-transfection by centrifugation (500g, RT, 5 min) and supernatants
were stored at -80°C.
3.4 Determination of Rituximab titer
[0062] Rituximab titer was determined in 200 mL three-fold diluted supernatants using an Octet RED96 (ForteBio, Pall,
Menlo Park, CA, USA) essentially as previously described [Grav LM et al., 2015], but with an increased shaking speed
of 1000 rpm.
3.5 Calculation of productivity parameters
[0063] Integral of viable cell density (IVCD) and daily specific production rate were calculated as described elsewhere
[45]. In short, the IVCD was calculated as the sum of the area under the curve for viable cell density. The area was
calculated - for each interval between samples - by multiplication of the elapsed time with the average cell density in the
interval. The daily specific production rate was calculated as the increase in product concentration divided by the IVCD
since last measurement.
3.6 Statistical analysis
[0064] Data (fold-changes) were tested for normality by D’Augustino-Pearson omnibus test using GraphPad Prism
software (version 6.05 for Windows, GraphPad Software, La Jolla, CA, USA). Data (non-transformed and log2-trans-
formed) in some groups did not pass the normality test, so statistical significance (p≤0.05) was assessed by performing
the Mann-Whitney nonparametric test (two-tailed) on non-transformed fold-changes using GraphPad Prism software.
Outliers were assessed by performing Grubb’s test (p≤0.05) using GraphPad Prism software.
3.7 Results:
[0065] Higher specific and volumetric productivity was observed for CHO cells expressing Rituximab IgG antibody
heavy chain (HL) and light chain (LC) having the signal peptides SP1-SP5, SP7, and SP11, as compared to CHO cells
compared to cells expressing Rituximab IgG antibody (heavy and light chains) having the signal peptide SP_IFNγ or
either of the synthetic signal peptides SYN1 and SYN2 (Figure 3a-b). In respect of CHO cells expressing Rituximab IgG
Table 5. Vectors used as PCR templates
Vector name Elements Source
pBudCE4.1 EF-1a, light chain Rituximab, heavy chain Rituximab Life Technologies
pcDNA3.1(+) pCMV, BGH pA, pSV40-NeoR-SV40 pA, pSV40-HygR-SV40 pA Life Technologies
pU0002 AmpR, pUC19 replication origin Lund et al., 2014
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antibody (heavy and light chains) having the signal peptides SP6, the IgG titer was below the detection limit for SP6,
despite having the correct vector sequence.
[0066] IVCD was increased for SP8, SP9, SP12 and SYN2 compared to SP_IFNγ (Figure 4c). For these four signal
peptide constructs we observed a correlation between IVCD and titer in contrast to no correlation for signal peptide
constructs with no increase in IVCD (SP1, SP2, SP4 and SP_IFNγ) (Figure 4c). Since low transfection efficiency gives
rise to faster growth (our unpublished observations), we speculate that the faster growth for the clones comprising the
SP8, SP9, SP12 and SYN2 signal peptides was due to experimental variations leading to a relatively low transfection
efficiency.
Example 4 In silico re-evaluation of signal peptides fused to Rituximab IgG antibody
[0067] All signal peptides fused to Rituximab HC and LC were re-evaluated to examine if prediction could be achieved.
[0068] According to both in silico programs SignalP and PredSi, the tested peptide SP6 did not contain a signal peptide;
which was consistent with the failure of CHO cells comprising the vector encoding the SP6- Rituximab HC and LC fusion
to express detectable levels of Rituximab IgG.
[0069] Re-evaluation of all other tested signal peptides by SignalP confirmed the original prediction that they were
signal peptides.
Example 5 In vivo testing of native CHO signal peptides secretion rate of secreted alkaline phosphatase (SEAP)
[0070] In this example, the signal peptides are tested with a commonly used mammalian secretion reporter protein,
secreted alkaline phosphatase (SEAP).
5.1 Vector design and construction
[0071] Expression vectors were constructed, as described in Example 3, comprising a nucleotide coding sequence
for each of the 13 selected native CHO signal peptides fused to the coding sequence for mature SEAP polypeptide
(SEQ ID No.:88), whereby the native SEAP signal peptide (present in the SEAP precursor polypeptide [SEQ ID No.:90]
was substituted with each of the 13 selected native CHO signal peptides. For comparison, expression plasmids comprising
the coding sequences for two synthetic signal peptides (SYN1 and SYN2) and the signal peptide from human interferon-
gamma, IFNγ (SP_IFNγ) were each similarly constructed for expression of SEAP (Table 3). These reference signal
peptides were chosen as comparators since they have been used (or are commonly used) in both commercial protein
production and gene therapy research. Expression vectors comprising each of the constructs were individually trans-
formed into CHO-S cells to produce transformed CHO-S cell lines. The rate of protein secretion facilitated by the signal
sequences was analyzed by use of a high-throughput screening platform of transient expression in CHO-S cells of each
transformed cell line.
5.2 Determination of SEAP titer
[0072] The concentration of secreted SEAP in the supernatant from each transformed cell line culture was determined
by a standard colormetric assay [Durocher et al, 2000]. Samples were taken and heat-treated at 65 deg C for 30 min.
50 ml of used culture medium was transferred to a new 96-well plate and mixed with 50 ml SEAP assay solution (20 nM
para-nitrophenyl phosphate (pNPP), 1 mM MgCl2, 1 M diethanolamine, pH adjusted to 9.8). Samples are measured as
dilution rows 1, 1:2, 1:4, 1:8, 1:16 to ensure getting enough measurements and avoiding overload. Absorbance is
measured at 410 nm at 1 min intervals to determine pNPP hydrolysis rates. EDTA is added to a final concentration of
10 mM to stop the reaction.
Example 6 In vivo testing of native CHO signal peptides secretion rate of erythropoetin (EPO)
[0073] In this example, the signal peptides are tested with a commercial pharmaceutical protein of the hormone type
erythropoetin (EPO).
6.1 Vector design and construction
[0074] Expression vectors were constructed, as described in Example 3, comprising a nucleotide coding sequence
for each of the 13 selected native CHO signal peptides fused to the coding sequence for mature EPO (SEQ ID
NO:92)whereby the native EPO signal peptide was substituted with each of the 13 selected native CHO signal peptides.
For comparison, expression plasmids comprising the coding sequences for two synthetic signal peptides (SYN1 and
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SYN2) and the signal peptide from human interferon-gamma, IFNγ (SP_IFNγ) were each similarly constructed for ex-
pression of SEAP (Table 3). These reference signal peptides were chosen as comparators since they have been used
(or are commonly used) in both commercial protein production and gene therapy research. Expression vectors comprising
each of the constructs were individually transformed into CHO-S cells to produce transformed CHO-S cell lines. The
rate of protein secretion facilitated by the signal sequences was analyzed by use of a high-throughput screening platform
of transient expression in CHO-S cells of each transformed cell line.
6.2 Determination of EPO titer
[0075] EPO titer was determined in 200 mL three-fold diluted supernatants derived from each transformed cell line
culture using an Octet RED96 (ForteBio, Pall, Menlo Park, CA, USA) essentially as previously described [Grav LM et
al., 2015], but with an increased shaking speed of 1000 rpm.
Example 7 In vivo testing of native CHO signal peptides secretion rate of the receptor-antibody fusion protein 
Enbrel/Etanercept/Etacept/Benepali/ Brenzys
[0076] In this example, the signal peptides are tested with a pharmaceutical tumor necrosis factor (TNF) inhibitor
fusion protein of the TNF and the constant region of human IgG1 (Enbrel).
7.1 Vector design and construction
[0077] Expression vectors were constructed, as described in Example 3, 5 and 6, comprising a nucleotide coding
sequence for each of the 13 selected native CHO signal peptides fused to the coding sequence for mature Enbrel (SEQ
ID No.:94) whereby the native Enbrel signal peptide (present in the Enbrel precursor polypeptide [SEQ ID No.:96]was
substituted with each of the 13 selected native CHO signal peptides. For comparison, expression plasmids comprising
the coding sequences for two synthetic signal peptides (SYN1 and SYN2) and the signal peptide from human interferon-
gamma, IFNγ (SP_IFNγ) were each similarly constructed for expression of SEAP (Table 3). These reference signal
peptides were chosen as comparators since they have been used (or are commonly used) in both commercial protein
production and gene therapy research. Expression vectors comprising each of the constructs were individually trans-
formed into CHO-S cells to produce transformed CHO-S cell lines.The rate of protein secretion facilitated by the signal
sequences was analyzed by use of a high-throughput screening platform of transient expression in CHO-S cells of each
transformed cell line.
7.2 Determination of Enbrel titer
[0078] Enbrel titer was determined in 200 mL three-fold diluted supernatants derived from each transformed cell line
culture using an Octet RED96 (ForteBio, Pall, Menlo Park, CA, USA) essentially as previously described [Grav LM et
al., 2015], but with an increased shaking speed of 1000 rpm.
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Claims
1. A recombinant gene for expression of a precursor polypeptide, the gene comprising an in-frame fusion of:
a. a first nucleic acid molecule encoding a signal peptide, and
b. a second nucleic acid molecule encoding a recombinant polypeptide, wherein the fused first and second
nucleic acid molecules encode the precursor polypeptide, and wherein the signal peptide is between 15 and
25 amino acid residues in length and comprises an amino acid sequence selected from the group consisting
of: SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6], SP4 [SEQ ID No.:8], SP5 [SEQ ID No.: 10],
SP7 [SEQ ID No.:14] and SP11 [SEQ ID No.:22].
2. The recombinant gene for expression of a precursor polypeptide according to claim 1, wherein the recombinant
polypeptide is selected from the group consisting of a hormone, enzyme, immunoglobulin heavy chain, immunoglob-
ulin light chain, whole immunoglobulin, fragment antigen-binding (Fab) fragment, Fc fragment, single-chain variable
fragment (scFv), cytokine, interleukin, complement factor, coagulation factor, an extracellular matrix protein, and a
soluble receptor.
3. The recombinant gene for expression of a precursor polypeptide according to claim 1 or 2, wherein the gene is
operably linked to a promoter DNA molecule.
4. The recombinant gene for expression of a precursor polypeptide according to any one of claims 1 to 3, wherein the
gene is operably linked to a terminator DNA molecule.
5. A vector comprising the recombinant gene for expression of a precursor polypeptide according to any one of claims
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1 to 4.
6. A genetically modified CHO cell transformed with the recombinant gene for expression of a precursor polypeptide
according to any one of claims 1 to 4.
7. The genetically modified CHO cell according to claim 6, wherein said cell is derived from a CHO cell line selected
from the group consisting of: CHO-K1, CHO-S or GS-CHO, CHO-Lec1, CHO-Lec10, CHO-Lec13, CHO Pro-5, CHO
DX B11 and CHO DG44 cells.
8. A method for producing a recombinant protein in vivo comprising:
a. providing one or more genetically modified CHO cells transformed with a recombinant gene according to
claim 6 or 7;
b. introducing said one or more genetically modified CHO cells into a culture medium to produce a culture;
c. incubating the culture;
d. recovering the produced recombinant polypeptide from the culture, and optionally
e. purifying the recombinant polypeptide recovered.
9. A method for producing a recombinant polypeptide in vivo according to claim 8, wherein the cell-specific productivity
of recombinant polypeptide by the CHO cell is enhanced in comparison to a CHO cell wherein the encoded signal
peptide is a cognate native signal peptide of the recombinant polypeptide or a non-CHO-derived signal peptide.
10. Use of a signal peptide to enhance the production of a recombinant polypeptide in a genetically modified CHO cell,
wherein the signal peptide is fused to the recombinant polypeptide, and wherein the signal peptide is between 15
and 25 amino acid residues in length and comprises an amino acid sequence selected from the group consisting
of: SP1 [SEQ ID No.:2], SP2 [SEQ ID No.:4], SP3 [SEQ ID No.:6], SP4 [SEQ ID No.:8], SP5 [SEQ ID No..:10], SP7
[SEQ ID No.:14] and SP11 [SEQ ID No.:22].
11. Use of a signal peptide to enhance the production of a recombinant polypeptide in a genetically modified CHO cell
according to claim 10, wherein the recombinant polypeptide is selected from the group consisting of a hormone,
enzyme, immunoglobulin heavy chain, immunoglobulin light chain, whole immunoglobulin, fragment antigen-binding
(Fab) fragment, Fc fragment, single-chain variable fragment (scFv), cytokine, interleukin, complement factor, coag-
ulation factor, an extracellular matrix protein, and a soluble receptor.
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